CBMG
AbelZeta Pharma is a global clinical-stage biopharmaceutical company focused on discovering and developing T cell–based therapeutics to treat cancer and inflammatory and immunological diseases. The company emphasizes its proprietary platforms for adoptive cell therapy, including CAR-T and tumor-infiltrating lymphocytes (TIL), targeting hematologic malignancies and solid tumors. Its research and development operates globally, with emphasis on advancing immunotherapies from pipeline through clinical trials to address oncology and immune-mediated conditions.
No recent news for this company.